In the cancer type multiple myeloma, the malignant cells differ significantly from normal cells regarding the layer of ...

In two Phase I expansion cohorts, the firm is studying KTX-1001 with BMS's mezigdomide or Onyx's carfilzomib in patients with t(4;14) translocations.

For patients with multiple myeloma who have undergone multiple lines of treatment and are refractory to common agents, new therapies offer remarkable hope. With 3 BCMA-targeted bispecific antibodies ...

Medically reviewed by Archana Sharma, DO Multiple myeloma is a chronic (long-term) blood cancer that affects plasma cells made in the bone marrow, which is spongy tissue found inside bones. While ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...

Absence of a clear overall survival advantage in phase III trials fuels debate on the value, timing of transplant ...

Multiple myeloma—a cancer of the plasma cells in the bone marrow—poses unique challenges, particularly for Black Americans.

Researchers sought to determine whether ide-cel would be a safe and effective treatment for patients with multiple myeloma in a real-world setting.